Veera Mustonen recently joined Spinverse as a Senior Manager. She leads an experienced and international Smart Cities and Mobility team with a wide variety of technology, industry and city management capabilities. Veera and her team support Spinverse customers in building and running complex mobility and city ecosystems and international consortia across organisations of all types. We had a chat with Veera about the future insights of this sector, which has been close to her heart for almost a decade.
Our People (3)
This spring and summer,we were seeking for several new experts to join our ranks, and we are now gradually onboarding our newly hired colleagues. They will help our customers grow through public funding in health tech, defence and security, smart city & mobility, manufacturing industries, and ICT & electronics. Warm welcome to Renuka, Cloé, Veera, Robert, Simo-Pekka, Sameer and Diederick.
We know the warmest time of the year is not far away when our summer trainees join Spinverse to support our experts over the summer holiday season. This year, we are proud to introduce Maria Heinonen, Heidi Melkko and Joonas Paukkunen as our summer trainees. They were selected in our virtual recruitment event from more than 150 candidates.
Spinverse business continues to grow and renew to meet the customer needs and to offer top expertise on public funding, and existing or emerging technologies. As our experts accumulate more experience with Spinverse, we try to offer opportunities to take on new responsibilities. At the same time, we warmly welcome new experts to join our ranks. This spring, we have had several recruitment processes in our business units and are now proud to introduce our latest promotion and first new colleagues.
The main focus of more than 60 Spinverse experts is to innovate, ideate and challenge. This is why the company’s working environment called for inspirational spaces for innovation. Spinverse recently moved to Keilaniemi, Espoo, to larger premises and aimed to create an environment where employees can work in a variety of ways, meet colleagues and also celebrate success.
Spinverse founder and Chairman of the board Pekka Koponen shared his thoughts about Finland's recovery and resilience plan. What opportunities does the recovery package offer especially for Finnish industries, and how can board members promote the growth opportunities of their companies from this perspective? Read here Pekka's expert advice to companies and their executives.
When funding calls open and the consortium gears kick into action, there is a lot of excitement mixed with uncertainty and risk. Consortiums do not come fully formed, and risk is not just isolated to new technologies or organisational challenges. It is a combination of both and also includes other factors, such as regulation, ability of organisations to collaborate, global phenomenon, ships getting stuck in major trade arteries and so on. Spinverse's Patrick Halford, VP, Digital Industries discusses on how to manage consortium risk and how Spinverse can help.
In an interview with Finnish newspaper Kauppalehti, Pekka and Laura Koponen talk about the present and future of Spinverse. All large companies in Finland know the consulting company founded by Pekka Koponen, even though Spinverse may not ring a bell to the general public. The company is a very well-known collaboration partner to various large and also small and mid-sized companies, as it has helped them gain over 500 M€ in EU-funded money for R&D&I.
Last year was one of the busiest and most successful years to date for Spinverse. We welcomed many new colleagues, new customers and worked on exciting new projects. We are proud of our skilled colleagues who have worked so hard to help our customers and are delighted to share the latest news about promotions. What is more, warm welcome to our new colleagues in the Spinverse family.
Spinverse is one of the nine partners in the STARDUST project, launched in 2017, to create a miniaturised neurosurgical implant leading to a proof-of-concept for a new treatment approach for Parkinson’s disease. The four-year project has now progressed to its final year, coming a few steps closer to introduce novel ways to treat a wide variety of diseases.